NCT03599284 is a Phase 2 clinical trial of Vicagrel 5mg in Coronary Artery Disease, sponsored by Jiangsu vcare pharmaceutical technology co., LTD.

Who is sponsoring NCT03599284?

NCT03599284 is sponsored by Jiangsu vcare pharmaceutical technology co., LTD.

What drugs are being tested in NCT03599284?

Interventions in NCT03599284: Vicagrel 5mg, Vicagrel 6mg, Vicagrel 7.5mg, Clopidogrel 75mg.

What condition does NCT03599284 study?

NCT03599284 studies Coronary Artery Disease, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors.

Is NCT03599284 still recruiting?

NCT03599284 is currently completed. Last updated 23 September 2019.

Last reviewed 2019-09-23 · How we verify

NCT03599284

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel

Completed Phase 2 Last updated 23 September 2019

What this trial tests

Phase 2 trial testing Vicagrel 5mg in Coronary Artery Disease in 279 participants. Completed in 28 July 2019.

Timeline

30 August 2018

Primary endpoint
11 June 2019

28 July 2019

Quick facts

Lead sponsor	Jiangsu vcare pharmaceutical technology co., LTD
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	279
Start date	30 August 2018
Primary completion	11 June 2019
Estimated completion	28 July 2019
Sites	27 locations across China

Drugs / interventions tested

Vicagrel 5mg — full drug profile →
Vicagrel 6mg — full drug profile →
Vicagrel 7.5mg — full drug profile →
Clopidogrel 75mg — full drug profile →

Conditions studied

Coronary Artery Disease — all drugs for Coronary Artery Disease →
Percutaneous Coronary Intervention — all drugs for Percutaneous Coronary Intervention →
Platelet Aggregation Inhibitors — all drugs for Platelet Aggregation Inhibitors →

Sponsor

Jiangsu vcare pharmaceutical technology co., LTD — full company profile →

Who can join

Adults 18 to 75, any sex, with Coronary Artery Disease or Percutaneous Coronary Intervention. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-center, randomized, double-blind, triple-dummy, parallel-controled, dose-exploration phase II trial. Patients with coronary atherosclerotic heart disease and planned percutaneous coronary intervention （PCI） will be randomized after informed consent, in a 1:1:1:1 ratio to the following treatment groups: Experimental group 1 : Vicagrel 20mg loading followed by 5mg/day for 28 days; Experimental group 2 : Vicagrel 24mg loading followed by 6mg/day for 28 days; Experimental group 3 : Vicagrel 30mg loading followed by 7.5mg/day for 28 days; Control group : Clopidogrel 300mg loading followed by 75mg/day for 28 days. The primary purpose of this trial is to evaluate the efficacy, safety of vicagrel antiplatelet therapy and explore dose in patients with coronary atherosclerotic heart disease during and after PCI compared with clopidogrel.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting

Other Jiangsu vcare pharmaceutical technology co., LTD trials

Trials by the same sponsor.

NCT07533851 — A Food Effect Study of VC005 Tablets in Healthy Adult Subjects. · Phase 1 · not yet recruiting
NCT07172360 — Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis. · Phase 3 · recruiting
NCT07329101 — Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VC005 in Adolescent Subjects With Mild to Modera · Phase 1 · completed
NCT07172347 — Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo · Phase 2 · recruiting
NCT07067775 — Pharmacokinetic/Pharmacodynamic Study of Vicagrel Capsules and Clopidogrel Tablets in Healthy CYP2C19 Normal Metabolizer · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03599284 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jiangsu vcare pharmaceutical technology co., LTD
Last refreshed: 23 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03599284.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing